Surface activity and concentration dependent intestinal permeability in the rat

Pharmaceutical Research

Volumn 16, Issue 1, 1999, Pages 97-102

  Lindahl, Anders ^a   Persson, Bengt ^a   Ungell, Anna Lena ^b   Lennernäs, Hans ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b ASTRAZENECA R AND D   (Sweden)

Author keywords

Chlorpromazine; Drug absorption; Fluvastatin; Intestinal permeability; P glycoprotein; Surface activity; Surface tension; Verapamil

Indexed keywords

FLUINDOSTATIN; VERAPAMIL;

ANIMAL EXPERIMENT; ARTICLE; DRUG ABSORPTION; DRUG EFFECT; DRUG PENETRATION; INTESTINE MUCOSA PERMEABILITY; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; SURFACE TENSION;

ANIMALS; FATTY ACIDS, MONOUNSATURATED; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INDOLES; INTESTINAL ABSORPTION; MALE; PERMEABILITY; RATS; RATS, SPRAGUE-DAWLEY; SURFACE PROPERTIES; VERAPAMIL;

EID: 0032930330     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1018879014281     Document Type: Article

References (27)

1. A. Lindahl, R. Sandström, A.-L. Ungell, and H. Lennernäs. Concentration- and region-dependent intestinal permeability of fluvastatin in the rat. J. Pharm. Pharmacol. 50:737-744 (1998).
2. V. D. Makhey and P. J. Sinko. Regional functional expression of multidrug resistance efflux pumps, Pgp and MRP, in human and rat intestine. Pharm. Res. 14:S-646 (1997).
3. B. H. Stewart, E. L. Reyner, R. Stern, E. A. Zegarac, R. Boyd, and L. R. Whitfield. Atorvastatin inhibits the P-glycoprotein-mediated secretion of 3H-digoxin in Caco-2 cell monolayers. Pharm. Res. 14:S-671 (1997).
4. J. Dimitroulakos and H. Yeger. HMG-CoA reductase mediates the biological effects of retinoic acid on human neuroblastoma cells: lovastatin specifically targets P-glycoprotein-expressing cells. Nat. Med. 2:326-33 (1996).
5. M. Holmberg, C. Sandberg, P. Nygren, and R. Larsson. Effects of lovastatin on a human myeloma cell line: increased sensitivity of a multidrug-resistant subline that expresses the 170 kDa P-glycoprotein. Anticancer Drugs. 5:598-600 (1994).
6. A. T. Florence. Surfactant interactions with biomembranes and drug absorption. Pure & Appl. Chem. 53:2057-2068 (1981).
7. E. K. Anderberg, C. Nystrom, and P. Artursson. Epithelial transport of drugs in cell culture. VII: Effects of pharmaceutical surfactant excipients and bile acids on transepithelial permeability in monolayers of human intestinal epithelial (Caco-2) cells. J. Pharm. Sci. 81:879-87 (1992).
8. B. J. Aungst, H. Saitoh, D. L. Burcham, S.-M. Huang, S. A. Mousa, and M. A. Hussain. Enhancement of the intestinal absorption of peptides and non-peptides. J. Contr. Rel. 41:19-31 (1996).
9. T. Lindmark, T. Nikkila, and P. Artursson. Mechanisms of absorption enhancement by medium chain fatty acids in intestinal epithelial Caco-2 cell monolayers. J. Pharmacol. Exp. Ther. 275: 958-64 (1995).
10. T. Lindmark, Y. Kimura, and P. Artursson. Absorption enhancement through intracellular regulation of tight junction permeability by medium chain fatty acids in Caco-2 cells. J. Pharmacol. Exp. Ther. 284:362-9 (1998).
11. M. Tomita, M. Hayashi, T. Horie, T. Ishizawa, and S. Awazu. Enhancement of colonic drug absorption by the transcellular permeation route. Pharm. Res. 5:786-9 (1988).
12. M. Shima, K. Yohdoh, M. Yamaguchi, Y. Kimura, S. Adachi, and R. Matsuno. Effects of medium-chain fatty acids and their acylglycerols on the transport of penicillin V across Caco-2 cell monolayers. Biosci. Biotechnol. Biochem. 61:1150-5 (1997).
13. B. Persson, S. Nilsson, and L.-O. Sundelöf. On the characterization principles of some technically important water-soluble non-ionic cellulose derivatives. Part II: Surface tension and interaction with a surfactant. Carbohydr. Polym. 29:119-127 (1996).
14. P. D. Lundin, B. R. Westrom, N. Pantzar, and B. W. Karlsson. Bidirectional small intestinal permeability changes to different-sized molecules after HCl-induced injury in the rat. Dig. Dis. Sci. 42:677-83 (1997).
15. R. Sandström, A. Karlsson, and H. Lennernäs. The lack of stereo-selective P-glycoprotein mediated transport of R/S-verapamil across the rat jejunum. J. Pharm. Pharmacol. In Press (1998).
16. H. Toreson and B. M. Eriksson. Determination of fluvastatin enantiomers and the racemate in human blood plasma by liquid chromatography and fluorometric detection. J. Chromatogr. A. 729:13-18 (1996).
17. H. Lennernäs, Ö. Ahrenstedt, R. Hällgren, L. Knutson, M. Ryde, and L. K. Paalzow. Regional jejunal perfusion, a new in vivo approach to study oral drug absorption in man. Pharm. Res. 9:1243-1251 (1992).
18. I. Komiya, J. Y. Park, A. Kamani, N. F. H. Ho, and W. I. Higuchi. Quantitative mechanistic studies in simultaneous fluid flow and intestinal absorption using steroids as model solutes. Int. J. Pharmaceutics. 4:249-262 (1980).
19. A. T. Florence and D. Attwood, Physicochemical principles of pharmacy, Macmillan, London, 2nd ed., 1993.
20. P. M. Seeman and H. S. Bialy. The surface activity of tranquilizers. Biochem. Pharmacol. 12:1181-1191 (1963).
21. G. S. Retzinger, L. Cohen, S. H. Lau, and F. J. Kezdy. Ionization and surface properties of verapamil and several verapamil analogues. J. Pharm. Sci. 75:976-82 (1986).
22. J. A. Marqusee and K. A. Dill. Solute partitioning into chain molecule interphases: Monolayers, bilayer membranes, and micelles. J. Chem. Phys. 85:434-444 (1986).
23. D. M. Woodcock, M. E. Linsenmeyer, G. Chojnowski, A B. Kriegler, V. Nink, L. K. Webster, and W. H. Sawyer. Reversal of multidrug resistance by surfactants. Br. J. Cancer. 66:62-8 (1992).
24. S. Drori, G. D. Eytan, and Y. G. Assaraf. Potentiation of anticancer-drug cytotoxicity by multidrug-resistance chemosensitizers involves alterations in membrane fluidity leading to increased membrane permeability. Eur. J. Biochem. 228:1020-9 (1995).
25. A. Helenius and K. Simons. Solubilization of membranes by detergents. Biochim. Biophys. Acta. 415:29-79 (1975).
26. G. W. Gullikson, W. S. Cline, V. Lorenzsonn, L. Benz, W. A. Olsen, and P. Bass. Effects of anionic surfactants on hamster small intestinal membrane structure and function: relationship to surface activity. Gastroenterology. 73:501-11 (1977).
27. A. Lindahl, R. Sandström, A.-L. Ungell, B. Abrahamsson, T. W. Knutson, L. Knutson, and H. Lennernäs. Jejunal permeability and hepatic extraction of fluvastatin in humans. Clin. Pharmacol. Ther. 60:493-503 (1996).